Liu X J, Wang B, Jiang W G, Li Y J, Liu J B, Zhang M
Shandong University School of Medicine, Jinan, Shandong, China.
Shandong University School of Medicine, Jinan, Shandong, China
Genet Mol Res. 2015 Feb 20;14(1):1502-7. doi: 10.4238/2015.February.20.5.
Invasion, metastasis, and recurrence are the most common causes of death in patients with hepatocellular carcinoma (HCC) and are therefore critical factors for both therapy and prognosis. Current methods for diagnosis of HCC rely mainly on serological markers such as alpha-fetoprotein and liver enzymes, together with physical assessment and imaging techniques. The availability of more accurate serum markers may facilitate screening and early diagnosis, which will improve prognosis. This retrospective cohort analysis included 50 consecutive patients with cirrhosis and single or multifocal HCC and 40 control subjects with no liver disease or risk factors for viral hepatitis. Expression of epidermal growth factor-like domain 7 (EGFL7), osteopontin (OPN), and prostaglandin E2 (PGE2) were detected using an enzyme-linked immunosorbent assay. The mean serum levels of EGFL7, OPN, and PGE2 in the HCC group were 132.11 pg/mL, 11.77 ng/mL, and 179.37 pg/mL, respectively, which were all significantly higher than the levels in the control group (23.03 pg/mL, 2.31 ng/mL, and 47.36 pg/mL, respectively; P < 0.001). Serum levels of EGFL7, OPN, and PGE2 levels may thus be useful for screening and surveillance of HCC among high-risk populations, and have the potential to improve prognosis of these patients.
侵袭、转移和复发是肝细胞癌(HCC)患者最常见的死亡原因,因此是治疗和预后的关键因素。目前诊断HCC的方法主要依赖于血清学标志物,如甲胎蛋白和肝酶,以及体格检查和成像技术。更准确的血清标志物的可用性可能有助于筛查和早期诊断,从而改善预后。这项回顾性队列分析纳入了50例连续性肝硬化合并单灶或多灶HCC患者以及40例无肝病或病毒性肝炎危险因素的对照受试者。采用酶联免疫吸附测定法检测表皮生长因子样结构域7(EGFL7)、骨桥蛋白(OPN)和前列腺素E2(PGE2)的表达。HCC组中EGFL7、OPN和PGE2的平均血清水平分别为132.11 pg/mL、11.77 ng/mL和179.37 pg/mL,均显著高于对照组(分别为23.03 pg/mL、2.31 ng/mL和47.36 pg/mL;P < 0.001)。因此,EGFL7、OPN和PGE2的血清水平可能有助于在高危人群中筛查和监测HCC,并有可能改善这些患者的预后。